Dr. Herbst on Combination Therapies for Lung Cancer

Roy S. Herbst, MD, PhD
Published: Thursday, Jan 19, 2017



Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Now that pembrolizumab (Keytruda) has moved to the first-line setting, researchers are looking at combinations involving the agent, explains Herbst. Combinations such as pembrolizumab plus the VEGF inhibitor ramucirumab (Cyramza), pembrolizumab and a CTLA-4 inhibitor, as well as pembrolizumab and a targeted agent, are all being investigated.

There are also studies looking at genetics and immunohistochemistry to determine certain characteristics of patients who respond well to treatments versus patients who do not respond.
 
SELECTED
LANGUAGE


Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Now that pembrolizumab (Keytruda) has moved to the first-line setting, researchers are looking at combinations involving the agent, explains Herbst. Combinations such as pembrolizumab plus the VEGF inhibitor ramucirumab (Cyramza), pembrolizumab and a CTLA-4 inhibitor, as well as pembrolizumab and a targeted agent, are all being investigated.

There are also studies looking at genetics and immunohistochemistry to determine certain characteristics of patients who respond well to treatments versus patients who do not respond.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x